Quintiles Announces Clinical Pharmacology Alliance with AstraZeneca

Through the Alliance, Quintiles Will Support AstraZeneca`s Driveto Develop Its
Compounds to Optimum Quality, Speed and Efficiency
RESEARCH TRIANGLE PARK, N.C.--(Business Wire)--
Quintiles today announced that it has entered into in an industry-leading
clinical pharmacology alliance with AstraZeneca to deliver AstraZeneca`s
clinical pharmacology studies across multiple therapy areas and around the
globe.

As a result of the alliance, Quintiles will assume the operational
responsibilities for the majority of AstraZeneca`s clinical pharmacology
delivery. AstraZeneca and Quintiles will work together, focusing their efforts
on leveraging leading-edge science and establishing operational efficiency and
consistency to support AstraZeneca`s goal to shorten delivery timelines and
bring innovative medicines more quickly to patients.

The alliance is extensive and involves the engagement of a sole provider for
clinical pharmacology delivery, and a simple, standardized pricing model. Also,
as well as clinical conduct and medical oversight of studies, the agreement
covers a range of activities across the end-to-end study process.

Ron Wooten, Executive Vice President, Quintiles Corporate Development, said, "We
are delighted to be AstraZeneca`s dedicated clinical pharmacology alliance
strategic partner. This is an industry-leading alliance and demonstrates how, at
Quintiles, we`re helping the industry seize opportunities as the industry
transforms in response to the changing environment. As with any true alliance,
success depends not only on scientific, medical and operational excellence, but
also on creating a climate of trust, transparency, teamwork and joint
accountability. Our experience in managing such partnerships will be key as we
work together on this important project."

Commenting on the alliance, Anders Ekblom, Executive Vice President for Global
Drug Development, AstraZeneca, said, "This model gives us access to the right
scientific and medical expertise plus the quality, flexibility and capacity we
need to work efficiently and cost-effectively to deliver these studies. Finding
more efficient ways to do our work, whilst maintaining the highest quality, is
one of AstraZeneca`s key priorities. Our alliance with Quintiles will contribute
to AstraZeneca`s continued endeavors to develop better and better medicines
faster."

Quintiles has an industry leading, network of clinical pharmacology facilities
across Europe and the United States, and plans to open a unit in Asia in 2010.
These facilities are connected via integrated data platforms using advanced
electronic data capture and reporting to facilitate early go-no go decisions.

About Quintiles

Quintiles is the only fully integrated biopharmaceutical services company
offering clinical, commercial, consulting and capital solutions worldwide. The
Quintiles network of 23,000 engaged professionals in more than 50 countries
around the globe works with an unwavering commitment to patients, safety and
ethics. Quintiles helps biopharmaceutical companies navigate risk and seize
opportunities in an environment where change is constant. For more information,
please visit www.quintiles.com.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the
research, development, manufacturing and marketing of meaningful prescription
medicines and supplier for healthcare services. AstraZeneca is one of the
world`s leading pharmaceutical companies with healthcare sales of $31.6 billion
and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory,
oncology and infectious disease medicines. For more information about
AstraZeneca, please visit www.astrazeneca.com.

Quintiles
Media Relations:
Charlotte Taylor, +44 1344 708 386
media.info@quintiles.com
or
Investor Relations:
Greg Connors, +1 919-998-2000
invest@quintiles.com

Copyright Business Wire 2009